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Thwarting endogenous stress: BRCA
protects against aldehyde toxicity
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Homologous recombination (HR) and the
Fanconi Anemia (FA) pathways constitute
essential repair pathways for DNA damage,
which includes DNA double-stranded breaks
(DSB) and inter-strand cross-links (ICL),
respectively. Germline mutations affecting
a single copy of the HR factors BRCA1 and
BRCA2 predispose individuals to cancers of
the breast, ovary, prostate, and pancreas.
Cells deficient for BRCA proteins display
high levels of genome instability due to
defective repair of endogenous DSBs and
are also exquisitely sensitive to DNA-dama-
ging agents. In addition to their roles in
repair of DSBs and ICLs, HR and FA proteins
have a genetically separable function in the
protection of stalled DNA replication forks
from nuclease-mediated degradation
(Schlacher et al, 2012). Although it has been
hypothesized that loss of functional HR and
ICL repair is the primary cause of cancer in
BRCA- and FA-deficient patients (Prakash
et al, 2015), the contribution of replication
fork instability associated with the degra-
dation of nascent DNA remains unclear.
Two recent papers explain how endogenous
toxins render cells vulnerable to genomic
instability, which explains how the BRCA/FA
pathway suppresses tumorigenesis (Tacconi
et al, 2017; Tan et al, 2017).
See also: EMC Tacconi et al and SLW Tan
et al
R eactive aldehydes are intermediatesor final products of endogenous meta-bolic processes, which if not catabo-
lized, may form DNA-protein cross-links
(DPC) and ICLs. Seminal work from the labo-
ratory of K.J. Patel has shown that FA path-
way is essential to counteract these adducts,
which may form ICLs (Langevin et al, 2011).
Combined loss of FA pathway protein
FANCD2 and aldehyde catabolism enzymes
leads to an increased DNA damage load,
resulting in bone marrow failure and malig-
nancies in mutant mice (Langevin et al,
2011). Mutations in ALDH2, the enzyme
required for acetaldehyde metabolism, are
also associated with predisposition to cancer
signifying its critical role in the removal of
genotoxic metabolic intermediates (Cai et al,
2015). However, the mechanisms by which
aldehyde toxicity acts as a driver of tumorige-
nesis and whether BRCA1 and BRCA2 protect
against these lesions remained unclear.
New work from Madalena Tarsounas
shows that inactivation of HR factors BRCA1,
BRCA2, and RAD51 in cell lines results in
hypersensitization to either genetic ablation
or chemical inhibition of the acetaldehyde
metabolizing enzyme ALDH2 (Tacconi et al,
2017). Moreover, treatment with acetalde-
hyde in BRCA1- and BRCA2-deficient mouse
tumor models and patient-derived tumor
xenografts in vivo results in regression of
tumors. How does a DNA-damaging agent
like acetaldehyde lead to the inhibition of
tumor growth? Assuming that acetaldehyde
induces cross-links, DSB intermediates might
be expected to form after the replication fork
collides with the lesion, which would require
error-free repair by HR.
A well-known mechanism of chemother-
apy resistance in BRCA-deficient tumors
occurs through the restoration of HR (Lord &
Ashworth, 2013). One would therefore
predict that restoration of HR functions
would result in resistance to acetaldehyde.
However, Tacconi et al (2017) find that
BRCA1/53BP1-deficient tumors, which are
HR proficient, are exquisitely sensitive to
acetaldehyde treatments in vivo. This surpris-
ing observation might be explained by three
non-mutually exclusive mechanisms (Fig 1):
(i) While HR functions are restored, BRCA1
and 53BP1 double-deficient cells are not
protected from replication fork degradation
(Ray Chaudhuri et al, 2016), and acetalde-
hyde treatment induces replication stress in
these cells (Tacconi et al, 2017); (ii) BRCA1
has a role in cross-link repair upstream of its
role in HR, and BRCA1/53BP1-deficient cells
remain hypersensitive to DNA cross-links
(Bunting et al, 2012); (iii) a recent report
from the laboratory of Ashok Venkitaraman
has shown that exposure to aldehydes causes
selective degradation of BRCA2 resulting in
“induced haploinsufficiency” for BRCA2 (see
below) (Tan et al, 2017). The reduction in
the levels of BRCA2 upon acetaldehyde treat-
ments could result in HR defects that re-sensi-
tize BRCA1/53BP1-deficient tumors, which
were initially proficient for HR. In summary,
these studies suggest that BRCA-deficient
tumors could be sensitized by disrupting the
aldehyde metabolism pathway. Furthermore,
aldehyde might be effective in BRCA-defi-
cient tumors, which have re-established HR
and become resistant to chemotherapeutic
agents such as PARP inhibitors.
However, treatment with drugs such as
acetaldehyde can have both favorable as well
as adverse consequences. A recent report from
Venkitaraman and colleagues suggests that
exposure to endogenous aldehydes could also
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drive tumorigenesis in BRCA2 heterozygous
carriers (Tan et al, 2017). They show that
formaldehyde exposure of cells harboring
heterozygous pathogenic mutations in BRCA2
leads to increased genome instability. This
genome instability arises from replicative
stress induced by formaldehyde, which results
in degradation of nascent DNA. The replication
fork instability in BRCA2 heterozygous cells is
caused by the selective proteasomal degrada-
tion of BRCA2 protein upon formaldehyde
exposure. Interestingly, the increased genome
instability in BRCA2 heterozygous cells
induced by exposure to formaldehyde does not
result in loss of viability. This could be because
BRCA2 haploinsufficient cells can still partially
repair DSBs through HR. Tolerable but persis-
tent levels of DNA damage could thereby be
an initiating event in tumorigenesis.
In conclusion, therefore, these reports
have shed light on two important questions in
the DNA repair field: (i) What is the contribu-
tion of HR and replication fork stability in
preventing tumorigenesis and maintaining
cellular viability, and (ii) how do individuals
with BRCA heterozygosity develop tumors?
HR activity is essential for the survival of
organisms. For example, mice deficient for
BRCA1 and BRCA2 display embryonic lethal-
ity. Embryonic lethality in BRCA1-deficient
mice can be rescued by the deficiency of
53BP1, which results in restoration of HR,
whereas replication fork protection contri-
butes to genome stability but does not lead to
organismal viability (Ray Chaudhuri et al,
2016). The role of HR in preventing tumorige-
nesis is less clear. Cells from BRCA heterozy-
gous carriers support normal HR activity, yet
are haploinsufficient for protecting the
genome from unstable replication forks
(Pathania et al, 2014). Replication stress but
not HR deficiency is also characteristic of
BRCA2 mutations in mice which disrupt inter-
actions with PALB2, a protein which controls
BRCA2 functions in HR. Mono-allelic muta-
tions in PALB2 increase the risk of cancer,
and biallelic mutations cause FA (Hartford
et al, 2016). The mutant mice with disrupted
BRCA2/PALB2 interaction are viable but
exhibit high rates of tumorigenesis (Hartford
et al, 2016). In conclusion, persistent replica-
tion stress due to endogenous or environmen-
tal toxins such as reactive aldehydes may be
tumorigenic in cells partially compromised
for BRCA function. Since a high percentage of
the East Asian population carries a dominant-
negative allele of the aldehyde-catalyzing
enzyme ALDH2, studies investigating cancer
risk associated with BRCA1 and BRCA2 muta-
tions in this population will be important.
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Figure 1. Model for aldehyde sensitivity in BRCA-deficient tumors.
Breast tumors with BRCA1 mutations are sensitive to DNA-damaging agents like PARP inhibitors (PARPi) and
acetaldehyde due to defective homologous recombination (HR). However, these tumors have a high propensity
to develop resistance to drugs by acquiring secondary mutations in BRCA1 or in factors like 53BP1 and that
restore HR. Tan et al (2017) show that these PARPi-resistant, HR-proficient tumors are sensitive to acetaldehyde
treatments. The molecular mechanisms underlying this sensitivity can be explained by three mutually non-
exclusive mechanisms: (1) BRCA1 and 53BP1 double mutants are still defective for replication fork protection
although they are HR proficient. This could result in genome instability and loss of cellular viability. (2) BRCA1-
and 53BP-deficient cells are defective for cross-link repair as BRCA1 has roles in the repair of cross-links
upstream of HR. (3) Acetaldehyde treatments could result in selective degradation of BRCA2 proteins in these
HR-proficient cells rendering them HR deficient and thus making them hypersensitive to acetaldehyde
treatments. These mechanisms in concert could account for increased genome instability and cell death
observed in the HR-proficient PARPi-resistant tumors.
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